BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 17186542)

  • 21. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
    Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
    FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
    Chang AW; Kuo A; Barnathan ES; Okada SS
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
    de Witte H; Pappot H; Brünner N; Grøndahl-Hansen J; Hoyer-Hansen G; Behrendt N; Guldhammer-Skov B; Sweep F; Benraad T; Danø K
    Int J Cancer; 1997 Jul; 72(3):416-23. PubMed ID: 9247284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
    Hong SI; Park IC; Son YS; Lee SH; Kim BG; Lee JI; Lee TW; Kook YH; Min YI; Hong WS
    J Korean Med Sci; 1996 Feb; 11(1):33-7. PubMed ID: 8703368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
    Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
    Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
    Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of mesothelial cell mitogenesis by antisense oligonucleotides for the urokinase receptor.
    Shetty S; Kumar A; Johnson AR; Idell S
    Antisense Res Dev; 1995; 5(4):307-14. PubMed ID: 8746780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
    Lyon PB; See WA; Xu Y; Cohen MB
    Prostate; 1995 Oct; 27(4):179-86. PubMed ID: 7479384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
    Ploug M; Ellis V; Danø K
    Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction.
    Konakova M; Hucho F; Schleuning WD
    Eur J Biochem; 1998 Apr; 253(2):421-9. PubMed ID: 9654092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.
    Lund LR; Ellis V; Rønne E; Pyke C; Danø K
    Biochem J; 1995 Aug; 310 ( Pt 1)(Pt 1):345-52. PubMed ID: 7646466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transforming growth factor beta induces urokinase receptor expression in cultured retinal pigment epithelial cells.
    Sirén V; Myöhänen H; Vaheri A; Immonen I
    Ophthalmic Res; 1999; 31(3):184-91. PubMed ID: 10224501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
    Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne CK; Clark GM; Danø K; Grøndahl-Hansen J
    Breast Cancer Res Treat; 1995 Mar; 33(3):199-207. PubMed ID: 7749147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
    Reuning U; Wilhelm O; Nishiguchi T; Guerrini L; Blasi F; Graeff H; Schmitt M
    Nucleic Acids Res; 1995 Oct; 23(19):3887-93. PubMed ID: 7479032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V
    J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation and role of urokinase plasminogen activator in vascular remodelling.
    Tkachuk V; Stepanova V; Little PJ; Bobik A
    Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
    Kennedy S; Duffy MJ; Duggan C; Barnes C; Rafferty R; Kramer MD
    Br J Cancer; 1998 May; 77(10):1638-41. PubMed ID: 9635840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
    De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
    Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
    Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle UH; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V
    Biol Chem; 1997; 378(3-4):231-7. PubMed ID: 9165076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.